title: Interventional studies for polycystic ovarian syndrome in children and adolescents.
abstract: Polycystic ovarian syndrome (PCOS) is characterized by chronic anovulation, clinical and/or biochemical hyperandrogenism, which can be associated with altered insulin action. Symptoms usually begin around menarche, but onset after puberty may also occur as a result of environmental modifiers such as weight gain. The consequences of PCOS extend beyond the reproductive axis; there is a substantial risk for development of metabolic and cardiovascular abnormalities similar to the metabolic syndrome. Currently, the treatment is targeted to the patient's primary complaint such as hirsutism, restoration of regular menses or pregnancy. Pharmacological agents available for the treatment of hirsutism include androgen suppressors and peripheral androgen blockers. Recently, our understanding of the role of insulin resistance has led to the use of insulin-sensitizing medications as first-choice therapy. In conjunction with weight reduction and exercise, a pharmacologic reduction in insulin levels by either metformin or thiazolidinediones ameliorates both hyperinsulinemia and hyperandrogenism.
authors.affiliation: Children's Hospital at Montefiore, Albert Einstein College of Medicine, 3450 Bainbridge Ave, Bronx, NY 10467, USA, Tel.: +1 718 920 4664, , patricia.vuguin@einstein.yu.edu.
authors.forename: Patricia Myriam
authors.initials: PM
authors.lastname: Vuguin